ReviewRheumatology international2025
Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches.
Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Age-stratified treatment response in rheumatoid arthritis: a systematic review, meta-analysis, and integrated genetic and single-cell evidence implicating IL6R/TYK2 signaling.Clinical rheumatology · 2026Pooled it
- Treat-to-target strategies are feasible in elderly-onset rheumatoid arthritis given its reassuring risk-benefit profile.RMD open · 2026Trial
- Association of Clonal Hematopoiesis With Incident, Late-Onset, Seropositive Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Curcumin improves myocardial redox status in an experimental model of rheumatoid arthritis.Molecular and cellular biochemistry · 2026Article
- Reply.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Integrated transcriptomic analysis of peripheral blood CD4 + T cells identifies immune-associated hub genes in rheumatoid arthritis: discovery and external validation.Immunologic research · 2026Article
- Late-Onset Rheumatoid Arthritis and Air Pollution in a Multiethnic Cohort.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity.GeroScience · 2026Review
- Frontiers in Rheumatoid Arthritis: Emerging Research and Unmet Needs in Pharmacologic Management.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Clinical and Sonographic Pattern of Late-Onset and Early-Onset Rheumatoid Arthritis: Comparative Study.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
- Frailty in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: Current evidence and knowledge gaps.Therapeutic advances in musculoskeletal disease · 2026Review
- Late-onset systemic sclerosis: current concepts, uncertainties, and future practice guidelines.Reumatologia · 2026Article
- Targeting GM-CSF in Rheumatoid Arthritis: Advances in Cytokine-Directed Immunotherapy and Clinical Implications.Life (Basel, Switzerland) · 2025Review
- Rheumatoid Arthritis and Osteoporosis as Prototypes of Immunosenescence in Osteoimmunology: Molecular Pathways of Inflammaging and Targeted Therapies.International journal of molecular sciences · 2025Review
- Letter to the editor: social determinants of health in managing late-onset rheumatoid arthritis.Rheumatology international · 2025Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late-Onset Rheumatoid Arthritis (LORA) is receiving increased clinical attention due to global aging trends. LORA presents distinct diagnostic, clinical, and therapeutic challenges. It often presents with a balanced gender distribution, acute onset, preferential involvement of larger joints, and decreased seropositivity. The diagnostic process is complex due to atypical presentations, comorbidities, and limitations of classification criteria, which insufficiently address the heterogeneity of LORA phenotypes. Patients with LORA often experience age-related geriatric syndromes, including frailty, cognitive decline, and malnutrition, in addition to comorbid cardiovascular disorders, pulmonary involvement, oncologic conditions, and osteoporosis. All these factors confound disease progression and treatment strategies, necessitating careful consideration of polypharmacy and modified drug metabolism. While the treatment principles largely align with those of Younge-Onset Rheumatoid Arthiritis (YORA), LORA management requires individualized approaches. Available evidence suggests that with proper monitoring, disease-modifying anti-rheumatic drugs (DMARDs) are safe and effective for older adults. Glucocorticoids should be minimized due to potential detrimental effects. Despite elevated baseline disease activity and functional deterioration, effectively managed LORA patients may achieve disease control similar to that of younger individuals. This review advocates for age-adjusted diagnostic strategies and patient-centered care models tailored to the needs of older RA patients. Addressing these unmet needs may enhance outcomes and quality of life for the growing population of LORA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.